524816 Stock Overview
A pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
NATCO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,418.75 |
| 52 Week High | ₹1,638.35 |
| 52 Week Low | ₹789.00 |
| Beta | 0.55 |
| 1 Month Change | 4.63% |
| 3 Month Change | -1.55% |
| 1 Year Change | 79.12% |
| 3 Year Change | 67.57% |
| 5 Year Change | 146.63% |
| Change since IPO | 50,569.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524816 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.6% | 0.8% | -4.3% |
| 1Y | 79.1% | 39.7% | 19.1% |
Return vs Industry: 524816 exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 524816 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| 524816 volatility | |
|---|---|
| 524816 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 524816 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524816's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,016 | Rajeev Nannapaneni | www.natcopharma.co.in |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.
NATCO Pharma Limited Fundamentals Summary
| 524816 fundamental statistics | |
|---|---|
| Market cap | ₹253.79b |
| Earnings (TTM) | ₹19.45b |
| Revenue (TTM) | ₹45.64b |
13.0x
P/E Ratio5.6x
P/S RatioIs 524816 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524816 income statement (TTM) | |
|---|---|
| Revenue | ₹45.64b |
| Cost of Revenue | ₹6.95b |
| Gross Profit | ₹38.69b |
| Other Expenses | ₹19.24b |
| Earnings | ₹19.45b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 108.58 |
| Gross Margin | 84.78% |
| Net Profit Margin | 42.61% |
| Debt/Equity Ratio | 2.8% |
How did 524816 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield5%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NATCO Pharma Limited is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |